Chengyou Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chengyou Shi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Huimin Zhao
University of Illinois Urbana-Champaign, USA
2 shared publications Aashutosh Girish Boob
Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, USA
1 shared publication- Alexander J. Battiste
Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, USA
1 shared publication - Andrew J. Rice
Department of Biochemistry, School of Medicine – Basic Sciences, Vanderbilt University Medical Research Building-IV, Nashville, Tennessee, 37232, USA
1 shared publication Autumn M. Frerk
Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, USA
1 shared publicationBehnam Enghiad
Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, USA
1 shared publication
Latest Publications
- Open Access
- 17 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
A scalable platform to discover antimicrobials of ribosomal origin
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new antimicrobials in the face of rising antibiotic resistance. Here, we report a scalable platform that combines high-throughput bioinformatics with automated biosynthetic gene cluster refactoring for rapid evaluation of uncharacterized gene clusters. As a proof of concept, 96 RiPP gene clusters that originate from diverse bacterial phyla involving 383 biosynthetic genes are refactored in a high-throughput manner using a biological foundry with a success rate of 86%. Heterologous expression of all successfully refactored gene clusters inEscherichia colienables the discovery of 30 compounds covering six RiPP classes: lanthipeptides, lasso peptides, graspetides, glycocins, linear azol(in)e-containing peptides, and thioamitides. A subset of the discovered lanthipeptides exhibit antibiotic activity, with one class II lanthipeptide showing low µM activity againstKlebsiella pneumoniae, an ESKAPE pathogen. Overall, this work provides a robust platform for rapidly discovering RiPPs.
- 17 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessA scalable platform to discover antimicrobials of ribosomal origin
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new antimicrobials in the face of rising antibiotic resistance. Here, we report a scalable platform that combines high-throughput bioinformatics with automated biosynthetic gene cluster refactoring for rapid evaluation of uncharacterized gene clusters. As a proof of concept, 96 RiPP gene clusters that originate from diverse bacterial phyla involving 383 biosynthetic genes are refactored in a high-throughput manner using a biological foundry with a success rate of 86%. Heterologous expression of all successfully refactored gene clusters inEscherichia colienables the discovery of 30 compounds covering six RiPP classes: lanthipeptides, lasso peptides, graspetides, glycocins, linear azol(in)e-containing peptides, and thioamitides. A subset of the discovered lanthipeptides exhibit antibiotic activity, with one class II lanthipeptide showing low µM activity againstKlebsiella pneumoniae, an ESKAPE pathogen. Overall, this work provides a robust platform for rapidly discovering RiPPs.
- Open Access
- 16 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
PlasmidMaker is a versatile, automated, and high throughput end-to-end platform for plasmid construction
Plasmids are used extensively in basic and applied biology. However, design and construction of plasmids, specifically the ones carrying complex genetic information, remains one of the most time-consuming, labor-intensive, and rate-limiting steps in performing sophisticated biological experiments. Here, we report the development of a versatile, robust, automated end-to-end platform named PlasmidMaker that allows error-free construction of plasmids with virtually any sequences in a high throughput manner. This platform consists of a most versatile DNA assembly method using Pyrococcus furiosus Argonaute (PfAgo)-based artificial restriction enzymes, a user-friendly frontend for plasmid design, and a backend that streamlines the workflow and integration with a robotic system. As a proof of concept, we used this platform to generate 101 plasmids from six different species ranging from 5 to 18 kb in size from up to 11 DNA fragments. PlasmidMaker should greatly expand the potential of synthetic biology.
- 16 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessPlasmidMaker is a versatile, automated, and high throughput end-to-end platform for plasmid construction
Plasmids are used extensively in basic and applied biology. However, design and construction of plasmids, specifically the ones carrying complex genetic information, remains one of the most time-consuming, labor-intensive, and rate-limiting steps in performing sophisticated biological experiments. Here, we report the development of a versatile, robust, automated end-to-end platform named PlasmidMaker that allows error-free construction of plasmids with virtually any sequences in a high throughput manner. This platform consists of a most versatile DNA assembly method using Pyrococcus furiosus Argonaute (PfAgo)-based artificial restriction enzymes, a user-friendly frontend for plasmid design, and a backend that streamlines the workflow and integration with a robotic system. As a proof of concept, we used this platform to generate 101 plasmids from six different species ranging from 5 to 18 kb in size from up to 11 DNA fragments. PlasmidMaker should greatly expand the potential of synthetic biology.